U.S. market Closed. Opens in 2 days 6 hours 24 minutes

DFFN | Diffusion Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.17 - 5.19
52 Week Range 4.14 - 14.37
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 349,445
Average Volume 47,812
Shares Outstanding 2,040,289
Market Cap 8,977,272
Sector Healthcare
Industry Biotechnology
IPO Date 2008-05-23
Valuation
Profitability
Growth
Health
P/E Ratio -0.62
Forward P/E Ratio N/A
EPS -7.11
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 13
Country USA
Website DFFN
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
DFFN's peers: ADIL, AIM, AKTX, BNTC, BPTH, BRTX, CAPR, CLRB, IBIO, ITRM, JAGX, MBRX, PTN, PULM, SLNO, TNXP, IMNN, TOVX
*Chart delayed
Analyzing fundamentals for DFFN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see DFFN Fundamentals page.

Watching at DFFN technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DFFN Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙